3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
4
Completed
3
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Tumor-Agnostic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasm Metastasis
1
Interventions
Magnetic Resonance Spectroscopy
5
Cisplatin
5
Gemcitabine
4
trametinib
2
repotrectinib
2
pembrolizumab
2
enzalutamide
2
atezolizumab
2
Surveys and Questionnaires
2
SS1(dsFv)PE38
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Paclitaxel
2
Nivolumab
2
Interviews as Topic
2
Docetaxel
2
Cetuximab
2
Carboplatin
2
vinflunine
1
veliparib
1
vadimezan
1
toripalimab
1
talazoparib
1
sintilimab
1
reolysin
1
pixantrone
1
pertuzumab
1
peginterferon alfa-2a
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
pertuzumab
×
Tumor-Agnostic
×
Clear all
NCT03811418
2019-11-26
ATTILA
iOMEDICO AG
Phase 3
Withdrawn